NEUROCRINE BIOSCIENCES INC
For the period ended Sep 30, 2026. Filed Nov 2, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 2, 2026
NBIX$169.14+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Income and Comprehensive Income
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
AND COMPREHENSIVE INCOME
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| (in millions, except per share data) | 2026 | 2025 | 2026 | 2025 |
| Revenues: | ||||
| Net product sales | $1,119.0 | $789.9 | $2,884.3 | $2,035.6 |
| Collaboration revenues | 3.7 | 5.0 | 11.9 | 19.4 |
| Total revenues | 1,122.7 | 794.9 | 2,896.2 | 2,055.0 |
| Operating expenses: | ||||
| Cost of revenues, excluding amortization of acquired intangible assets | 26.6 | 13.0 | 63.5 | 31.5 |
| Research and development | 351.8 | 250.0 | 974.7 | 757.5 |
| Acquired in-process research and development | 11.7 | 0.3 | 34.4 | 0.4 |
| Selling, general, and administrative | 366.3 | 291.6 | 1,124.5 | 854.4 |
| Amortization of acquired intangible assets | 35.0 | 1.0 | 51.5 | 3.0 |
| Gain on sale of business, net of transaction costs | — | — | (28.6) | — |
| Total operating expenses | 791.4 | 555.9 | 2,220.0 | 1,646.8 |
| Operating income | 331.3 | 239.0 | 676.2 | 408.2 |
| Other (expense) income: | ||||
| Interest expense | (0.3) | — | (3.2) | — |
| Unrealized (loss) gain on equity investments | (52.3) | 30.6 | (25.8) | (6.7) |
| Investment income and other, net | 5.0 | 22.2 | 45.5 | 64.5 |
| Total other (expense) income, net | (47.6) | 52.8 | 16.5 | 57.8 |
| Income before provision for income taxes | 283.7 | 291.8 | 692.7 | 466.0 |
| Provision for income taxes | 77.2 | 82.3 | 143.9 | 141.1 |
| Net income | $206.5 | $209.5 | $548.8 | $324.9 |
| Foreign currency translation adjustments, net of tax | (0.1) | 1.6 | 0.5 | 3.9 |
| Unrealized (loss) gain on available-for-sale debt securities, net of tax | (0.6) | (0.9) | (9.2) | 3.5 |
| Comprehensive income | $205.8 | $210.2 | $540.1 | $332.3 |
| Earnings per share: | ||||
| Basic | $2.03 | $2.11 | $5.43 | $3.27 |
| Diluted | $1.96 | $2.04 | $5.26 | $3.19 |
| Weighted-average shares outstanding: | ||||
| Basic | 101.6 | 99.4 | 101.0 | 99.3 |
| Diluted | 105.2 | 102.5 | 104.3 | 102.0 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.